fbpx
close read more

ANNUAL REPORT

2020 / 2021

DOWNLOAD ANNUAL REPORT

EDITORIAL

OLIVIER LAUREAU, President of Servier

At Servier, we are undergoing a comprehensive transformation to better fulfil our vocation and maintain our independence. This requires us to focus firmly on our performance. We are extremely demanding when it comes to the selection of our R&D programs, we adapt our production facilities to suit the changes in our portfolio of medicines and consider how such changes may also affect the priorities of our global presence.

READ THE EDITORIAL →

THE YEAR IN PICTURES

  1. November 2020 MY HEALTH PARTNER, AN INNOVATIVE WEBSITE FOR PATIENTS
  2. December 2020 Going digital!
  3. December 2020 ONCOLOGY: NEW TREATMENT FOR PATIENTS IN BRAZIL
  4. January 2021 SERVIER CERTIFIED TOP EMPLOYER EUROPE!
  5. January 2021 PHARLAB INAUGURATES THREE NEW UNITS IN BRAZIL
  6. February 2021 NEW PRODUCTION UNIT AT THE ORIL INDUSTRIE FACILITY IN FRANCE
  7. March 2021 A GLOBAL STUDY FOR AND WITH PATIENTS WITH CHRONIC VENOUS DISEASE
  8. April 2021 ACQUISITION OF THE ONCOLOGY DIVISION OF AGIOS PHARMACEUTICALS
  9. April 2021 BOOSTING THE CORPORATE SAFETY CULTURE
  10. June 2021 SERVIER JOINS FORCES WITH BIOLABS TO MANAGE ITS START-UP INCUBATOR AT PARIS-SACLAY
  11. July 2021 EMPLOYEE ENGAGEMENT ON THE RISE!
  12. July 2021 NEW RESEARCH PARTNERSHIPS IN NEUROSCIENCE
  13. August 2021 POSITIVE RESULTS FROM AN INTERNATIONAL PHASE III CLINICAL TRIAL
  14. August 2021 APPROVAL TO MARKET A CHOLANGIOCARCINOMA MEDICINE IN THE US
  15. August 2021 SJOGREN’S SYNDROME—ENROLMENT OF THE FIRST PATIENT IN THE PHASE II CLINICAL TRIAL
LOOK BACK TO THE YEAR IN PICTURES→

RESPONDING TO THE CHALLENGES OF THE PHARMACEUTICAL INDUSTRY

CHALLENGE 1

EMPOWERING PATIENTS TO PLAY AN ACTIVE ROLE IN THEIR OWN HEALTH

Servier’s responses:

8th

Ranked (out of 33 companies) by oncology patient organizations according to the PatientView Report 2020 on the reputation of pharmaceutical companies

19

Collaborations with 19 international patient organizations in 2020/2021

18

Constitution of a working group involving 18 patients to improve interactions with patient organizations within the future Servier Research and Development Institute at Paris-Saclay

CHALLENGE 2

DEVELOPING NEW THERAPEUTIC APPROACHES

Servier’s responses:

2020

A antibody center of excellence developing high quality monoclonal and bi-specific antibodies following the acquisition of Symphogen in 2020

2023

2023: inauguration of the Bio-S bioproduction unit in Gidy, France that will cover all production stages of biotech medicines for preclinical and clinical trials and launch low-volume medicines on the market

1

A network for external innovation (China, US, France) to identify the most favorable opportunities in terms of research partnerships, licensing agreements and acquisitions with the most prominent centers for biomedical and life science innovation

CHALLENGE 3

HONING SPECIALIZATION
IN PRODUCTION FACILITIES

Servier’s responses:

1

Ongoing transformation of the Group’s production facilities in order to best respond to patient needs

16

production facilities throughout the world including 11 facilities for brand-name medicines

539

million standard boxes of brand-name medicines manufactured in 2020/2021

CHALLENGE 4

REMODELING AND DIGITIZING
WAYS OF WORKING

Servier’s responses:

3rd

annual employee engagement survey in 2021 with an 88% participation rate

80%

of employees would recommend Servier as a great place to work

4,17/51

Servier’s overall employee engagement score measured in June 2021

Source: annual engagement survey conducted with the Gallup Institute – 2021 Group results

CHALLENGE 5

FULFILLING EVER-INCREASING ENVIRONMENTAL AND SOCIAL EXPECTATIONS

Servier’s responses:

1

EcoDesign program to even more effectively integrate social and environmental concerns into the medicine life cycle

-25%

Target to reduce greenhouse gas emissions by 25% between 2016 and 2030 – and already a 13% reduction in greenhouse gas emissions per box of medicine produced in 2019 compared with 2016

40%

At least 40% of senior management positions held by women by 2024 – One of the Group’s targets from its #ServierDiversity CSR program (29% in 2021)

Financial Results

3.306 BN€

Revenue from brand-name medicines

4.725 BN€

2020/2021 Group revenue

4.3% annual growth (at constant exchange rates)

1.419 BN€

Revenue from generic medicines

FIND OUT MORE ABOUT →

TAKING
TANGIBLE ACTION

DOWNLOAD THE ANNUAL REPORT